Business Wire

SHIPPEO

9.5.2022 12:30:12 CEST | Business Wire | Press release

Share
Shippeo Introduces Carbon Visibility and Brings Powerful New Features to Ocean and Road Visibility

Shippeo , a leading provider of global and multimodal shipment visibility, today announced new products and major platform enhancements, as part of their feature-packed 2022 Spring platform release. The updates focus on customer satisfaction, new innovations, performance, and meeting evolving market needs. A new CO2 emissions calculator provides critical information on carbon emissions and other greenhouse gasses from supply chain transport and distribution for shippers, logistics service providers and carriers. Container tracking using Shippeo’s Ocean Visibility solution is now faster and easier with a new user experience and powerful monitoring capabilities. In addition, timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for the company’s market-leading Road Visibility product. Finally with the migration to Google Cloud and Snowflake, significant performance and scalability upgrades are added to the Shippeo platform.

“Our latest Spring platform release is packed full of new features and capabilities for customers,” explains Anand Medepalli, Chief Product Officer at Shippeo, “including a completely new Carbon Visibility offering for accurately calculating CO2 and other greenhouse gas emissions at the shipment level, as well as major enhancements to our Ocean and Road visibility solutions. We are evolving our platform to not only meet the needs of our customers today, but also to solve tomorrow’s supply chain problems. This is the first release in a new twice-yearly Spring and Autumn Shippeo platform release cycle, representing a shift to more regular and regimented platform updates. This reliability and momentum will help us to keep ahead and continue to offer the most innovative real-time visibility platform experience for users, more powerful capabilities to increase productivity, and higher data quality to improve ROI for our customers.”

Accurate, consolidated CO2 emissions monitoring for shippers and carriers
Carbon Visibility offers shippers and logistics service providers a consolidated view of CO2 emissions for upstream and downstream transport and distribution activities in one place, bringing a number of new capabilities to help companies monitor progress towards sustainability objectives.

Carriers also benefit from the new Carbon Visibility offering, allowing them to avoid the time consuming manual work that they are faced with today to calculate emissions on behalf of their clients. Carriers can now use Shippeo to instantly generate CO2 emission reports, which should allow them to more easily allocate CO2 emissions from a single vehicle to multiple customers in LTL/groupage scenarios based on their business rules.

The Shippeo Carbon calculator follows the GLEC framework and is compliant with EN 16258 and GHG protocol.

Advanced container tracking over ocean
Major enhancements to Ocean Visibility will help supply chain and transport managers track and manage container shipments more productively, with new features and a revamped user experience, including:

  • More detailed container event information with new AIS-based milestones and precise geofencing
  • A revamped order detail page displaying all relevant container tracking information
  • Ability to identify deviations from status information provided by ocean carriers
  • An updated global map providing a holistic view of ocean shipments, by vessel or individual container
  • New filters making searching for containers easier
  • Higher overall data quality with inputs from new data sources

Road tracking enhancements
Timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for Road Visibility , offering customers an even more powerful over-the-road shipment tracking solution.

  • ETA accuracy improves 32% thanks to AI/ML algorithm advancements, upgraded Dataiku ML Ops platform infrastructure and data science methodology advancements
  • Shuttle flow tracking enables better differentiation between shipments within multiple back-and-forth tours for more accurate departure and arrival times
  • Quality Newsletters notify users of data tracking rates and provides steps for improving tracking quality
  • Improved visibility and readability of information, with new tagged events and links between map and timeline views

Infrastructure improvements to boost data quality and user experience
Shippeo’s platform has been migrated to Google Cloud Platform in its entirety, representing a major improvement in infrastructure. The shift ensures significant scalability, performance and localization capabilities along with enhanced security for customers.

Alongside the platform feature additions and enhancements, Shippeo has also continued to double-down on higher data quality, an area in which the company consistently leads the market. Continued investment of significant capital into R&D aims to advance the platform’s AI/ML capabilities even further.

To that point, the data warehouse powering Shippeo Insights is now migrated to Snowflake , a state-of-the-art high-performance analytics database that has managed to reduce Shippeo dashboard loading times by 50% on average and up to 90% for large customers.

About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com

LinkedIn , Facebook , Twitter

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye